Company news
Jianmin Pharmaceutical Group Co Ltd. Class A (SSE:600976) news
Jianmin Pharmaceutical Group Co Ltd. Class A news releases on 6ix. Latest, Sep 4, 2026: "Jianmin Pharmaceutical Group Co., Ltd."Announcement on Approval…
Press releases & updates
"Jianmin Pharmaceutical Group Co., Ltd."Announcement on Approval for Marketing of Crisaborole Ointment
September 3, 2026
"Jianmin Pharmaceutical Group Co., Ltd."Semi-annual Report for 2026
August 19, 2026
"Jianmin Pharmaceutical Group Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing
August 17, 2026
"Jianmin Pharmaceutical Group Co., Ltd."Announcement on Inclusion of the Company's Products in the "National Essential Medicines List"
July 9, 2026
"Jianmin Pharmaceutical Group Co., Ltd."Announcement on Attending the 2026 Collective Reception Day for Investors of Listed Companies in Hubei Jurisdiction
July 1, 2026
"Jianmin Pharmaceutical Group Co., Ltd."Announcement on Obtaining Notice of Approval for Drug Clinical Trials
June 30, 2026
Announcement on Implementation of Dividend Distribution for 2025
April 20, 2026
Announcement on Resolutions of the 8th Meeting of the 11th Board of Directors
April 17, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
April 10, 2026
Announcement on Resolutions of the 7th Meeting of the 11th Board of Directors
March 20, 2026
Announcement on Convening the 2025 Annual Performance Briefing
March 16, 2026
Announcement on Resolutions of the 6th Meeting of the 11th Board of Directors
January 23, 2026
Announcement on the Approval of Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution for Marketing
December 10, 2025
Announcement on Implementation of Providing Guarantee for Subsidiary's Bank Credit Line
November 26, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trial
October 27, 2025
Report for Q3 2025
October 21, 2025
Announcement on Convening the Performance Briefing in Q3 2025
October 14, 2025
Announcement on the Approval of Furosemide Oral Solution for Marketing
September 1, 2025
Announcement on Resolutions of the 2nd Meeting of the 11th Board of Directors
August 19, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 12, 2025
Announcement on Resolutions of the 1st Meeting of the 11th Board of Directors
July 30, 2025
Announcement on Engaging in Asset Pool Business
July 14, 2025
Announcement on the Waiver of the Preemptive Right to Acquire Equity Interests in an Associated Enterprise and Other Related Matters
July 4, 2025
Announcement on Attending the 2025 Online Collective Reception Day for Investors of Listed Companies in Hubei Jurisdiction
June 9, 2025
Announcement on Resignation of Senior Management Member
May 9, 2025
Announcement on Implementation of Dividend Distribution for 2024
April 23, 2025
Announcement on the Approval of Pediatric Bezoar Antipyretic Plaster for Marketing
April 21, 2025
Announcement on Resolution of the 34th Meeting of the 10th Board of Directors
April 18, 2025
Announcement on Resolution of the 2024 Annual General Meeting
April 15, 2025
Announcement on Resolutions of the 16th Meeting of the 10th Board of Supervisors
March 21, 2025
Announcement on Convening 2024 Annual Performance Briefing
March 17, 2025
Implementation Announcement on Providing Guarantee for Bank Credit Lines of Subsidiary
January 22, 2025
Announcement on External Donations
January 13, 2025
Announcement on Resolution of the 30th Meeting of the 10th Board of Directors
December 17, 2024
Announcement on Resolution of the 2nd Extraordinary General Meeting in 2024
December 12, 2024
Announcement on Inclusion and Renewal of the Company's Products on the Catalogue of Drugs for Basic National Medical Insurance (2024)
November 28, 2024
Notice on Convening the 2nd Extraordinary General Meeting in 2024
November 26, 2024
Announcement on Election of Director to Act as Chairman
October 18, 2024
Announcement on Holding the Performance Briefing for Q3 2024
October 11, 2024
Announcement on Resolution of the 1st Extraordinary General Meeting in 2024
September 30, 2024
Announcement on the Second Unlocking of Restricted Stock Involved in the 2022 Restricted Stock Incentive Plan
September 13, 2024
Announcement on Obtaining the Drug Registration Certificate
August 27, 2024
2024 Semi-annual Report Full Text
August 15, 2024
Announcement on Convening Semi-annual Performance Briefing 2024
August 8, 2024
Announcement on Obtaining the "Drug Registration Certificate"
July 5, 2024
Announcement on 3rd Release and Circulation of Restricted Shares Involved in "2021 Restricted Shares Incentive Plan"
May 24, 2024
Announcement on Implementation of Providing Guarantees for Subsidiaries' Bank Credit Lines
May 14, 2024
Announcement on Attending Online Collective Reception Day for Investors of Listed Companies in Hubei Jurisdiction in 2024
May 10, 2024
Announcement on Implementation of Dividend Distribution of 2023
April 19, 2024
Announcement on Marketing Approval of Terbutaline Sulfate Nebuliser Solution
April 15, 2024